Type 2 Diabetes MellitusPhase 3NCT01042977

Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease

A Phase 3 study testing Dapagliflozin in people with Type 2 Diabetes Mellitus and Cardiovascular Disease, run by AstraZeneca at 135 sites in 10 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Who is it for?: Ages 45 years and older
Conditions the study is for: Type 2 Diabetes Mellitus, Cardiovascular Disease, Inadequate Glycaemic Control
What is being tested?: Dapagliflozin
Type of treatment: Pill or oral medicine
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 964 participants
Where: 135 sitesin 10 countries
Study dates: Mar 2010to Dec 2012
Phase: Phase 3
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 45 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Type 2 diabetes mellitus.
Cardiovascular disease
Uninterrupted anti-diabetic treatment for at least 8 weeks before enrolment

Who cannot join

Patients with type 1 diabetes or diabetes insipidus
Patients with 3 or more oral anti-hyperglycaemic drugs with or without insulin and/or poorly controlled diabetes
Any clinically significant illness, which would compromise the patient's safety and their participation in the study

Trial locations and contacts

135 sites in 10 countries.

Country

City, postcode or hospital

135 sites in 10 countries

United States57 sites

Research Site
Alexandria, Louisiana
Research Site
Alexandria, Virginia
Research Site
Altoona, Pennsylvania
Research Site
Anaheim, California
Research Site
Asheboro, North Carolina
Research Site
Austin, Texas
Research Site
Aventura, Florida
Research Site
Avon, Indiana
Research Site
Bell Gardens, California
Research Site
Berlin, New Jersey
Research Site
Billings, Montana
Research Site
Birmingham, Alabama
Research Site
Boca Raton, Florida
Research Site
Bradenton, Florida
Research Site
Brick, New Jersey
Research Site
Brooksville, Florida
Research Site
Chino, California
Research Site
Chula Vista, California
Research Site
Cincinnati, Ohio
Research Site
Clearwater, Florida
Research Site
Corpus Christi, Texas
Research Site
Dallas, Texas
Research Site
Dania Beach, Florida
Research Site
Delray Beach, Florida
Research Site
Erie, Pennsylvania
Research Site
Fargo, North Dakota
Research Site
Franklin, Indiana
Research Site
Greenfield, Indiana
Research Site
Holland, Pennsylvania
Research Site
Huntington Beach, California
Research Site
Irving, Texas
Research Site
Kalamazoo, Michigan
Research Site
Lancaster, Pennsylvania
Research Site
Livonia, Michigan
Research Site
Los Angeles, California
Research Site
Manassas, Virginia
Research Site
Media, Pennsylvania
Research Site
Mission Hills, California
Research Site
Muncie, Indiana
Research Site
New Smyrna Beach, Florida
Research Site
Oklahoma City, Oklahoma
Research Site
Orlando, Florida
Research Site
Paducah, Kentucky
Research Site
Philadelphia, Pennsylvania
Research Site
Redondo Beach, California
Research Site
Richardson, Texas
Research Site
Riverside, California
Research Site
Rockville, Maryland
Research Site
Sacramento, California
Research Site
San Antonio, Texas
Research Site
San Diego, California
Research Site
Scottsdale, Arizona
Research Site
Springfield, Illinois
Research Site
Sugarland, Texas
Research Site
Topeka, Kansas
Research Site
Torrance, California
Research Site
Waterloo, Iowa

Other trials in United States

Poland25 sites

Research Site
Bialystok
Research Site
Chrzanów
Research Site
Gdansk
Research Site
Grodzisk Mazowiecki
Research Site
Iława
Research Site
Kielce
Research Site
Krakow
Research Site
Łęczna
Research Site
Łęczyca
Research Site
Lodz
Research Site
Lublin
Research Site
Mrągowo
Research Site
Nowy Sącz
Research Site
Płock
Research Site
Poznan
Research Site
Ruda Śląska
Research Site
Skierniewice
Research Site
Sopot
Research Site
Tarnów
Research Site
Torun
Research Site
Warsaw
Research Site
Wroclaw
Research Site
Zabrze
Research Site
Zgierz
Research Site
Zielona Góra

Other trials in Poland

Australia12 sites

Research Site
Adelaide, South Australia
Research Site
Bedford Park, South Australia
Research Site
Blacktown, New South Wales
Research Site
Box Hill, Victoria
Research Site
Broadmeadow, New South Wales
Research Site
Carina Heights, Queensland
Research Site
Heidelberg, Victoria
Research Site
Herston
Research Site
Hornsby, New South Wales
Research Site
Keswick, South Australia
Research Site
Kippa-Ring, Queensland
Research Site
Wollongong, New South Wales

Other trials in Australia

Canada12 sites

Research Site
Bay Roberts, Newfoundland and Labrador
Research Site
Calgary, Alberta
Research Site
Edmonton, Alberta
Research Site
Etobicoke, Ontario
Research Site
Halifax, Nova Scotia
Research Site
Mirabel, Quebec
Research Site
Moncton, New Brunswick
Research Site
Ottawa, Ontario
Research Site
Québec, Quebec
Research Site
Scarborough Village, Ontario
Research Site
Thornhill, Ontario
Research Site
Toronto, Ontario

Other trials in Canada

Hungary9 sites

Research Site
Ajka
Research Site
Balatonfüred
Research Site
Budapest
Research Site
Esztergom
Research Site
Győr
Research Site
Komárom
Research Site
Mosonmagyaróvár
Research Site
Tát
Research Site
Veszprém

Other trials in Hungary

Bulgaria8 sites

Research Site
Blagoevgrad
Research Site
Pernik
Research Site
Pleven
Research Site
Rousse
Research Site
Sevlievo
Research Site
Sofia
Research Site
Stara Zagora
Research Site
Varna

Other trials in Bulgaria

Argentina5 sites

Research Site
Buenos Aires, Buenos Aires F.D.
Research Site
Córdoba, Córdoba Province
Research Site
Rosario, Santa Fe Province
Research Site
Salta, Salta Province
Research Site
Santa Fe, Santa Fe Province

Other trials in Argentina

Germany5 sites

Research Site
Damme
Research Site
Dortmund
Research Site
Homburg
Research Site
Münster
Research Site
Wangen

Other trials in Germany

Austria1 site

Research Site
Vienna

Other trials in Austria

Chile1 site

Research Site
Santiago, Santiago Metropolitan

Other trials in Chile

About this study

Official title: A 24-week, Multicentre, Randomised, Double-blind,Age-stratified, Placebo Controlled Phase III Study With an 80-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin 10 mg Once Daily in Patients With T2DM and Cardiovascular Disease, Who Exhibit Inadequate Glycaemic Control on Usual Care

This study is carried out to assess whether dapagliflozin improves glycemic control, decreases fasting plasma glucose levels, body weight and blood pressure when added to patient's existing medications and how it compares with their usual treatment without added dapagliflozin. Safety data will be collected and analysed to confirm that treatment with dapagliflozin is safe and well tolerated in patients who have diabetes and cardiovascular disease

Conditions: Type 2 Diabetes Mellitus, Cardiovascular Disease, Inadequate Glycaemic Control
Being tested: Dapagliflozin, Placebo
Keywords: dapagliflozin, diabetes, cardiovascular disease
Medical subject headings: Diabetes Mellitus, Type 2, Cardiovascular Diseases, Diabetes Mellitus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

DapagliflozinDrug
10 mg tablet, oral, once daily, 24- week treatment and 80-week extension period
PlaceboDrug
matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period

Study groups in NCT01042977
Study group	Role	What they receive
1	Experimental	dapagliflozin 10 mg tablet Receives: Drug: Dapagliflozin
2	Placebo comparator	matching placebo tablet Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

Adjusted Mean Change in HbA1c Levels
To compare the glycemic efficacy of dapagliflozin 10 mg versus placebo when added to usual care in type 2 diabetes patients with cardiovascular disease, measured as the mean change in HbA1c from baseline to week 24.
Measured: Baseline to Week 24
Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit
To compare the clinical benefit of dapagliflozin 10 mg versus placebo when added to usual care in type 2 diabetes patients with cardiovascular disease at week 24, measured as the proportion of responders for a 3-item endpoint of clinical benefit, defined as an absolute drop of 0.5% or more from baseline HbA1c, and a relative drop of 3% or more from baseline for total body weight, and an absolute drop of 3 mmHg or more from baseline in seated systolic blood pressure.
Measured: Baseline to Week 24

Secondary outcomes (5)

Adjusted Mean Percent Change in Body Weight
To compare the mean percent change in body weight from baseline to week 24 between dapagliflozin 10 mg versus placebo.
Measured: Baseline to Week 24
Proportion of Participants With a Reduction From Baseline of 5% or More in Body Weight in Participants With Baseline BMI ≥27 kg/m²
To compare the proportion of participants with BMI baseline ≥27 kg/m2 with a reduction from baseline of 5% or more in body weight with dapagliflozin 10 mg versus placebo from baseline to week 24. Least Squares Mean represents the percent of participants adjusted for baseline body weight and age stratum.
Measured: Baseline to Week 24
Adjusted Mean Change in Systolic Blood Pressure at Week 8 (LOCF)
To compare the mean change in seated systolic blood pressure from baseline to week 8 between dapagliflozin 10 mg versus placebo.
Measured: Baseline to Week 8
Adjusted Mean Change in Seated Systolic Blood Pressure at Week 24 (LOCF)
To compare the mean change in seated systolic blood pressure from baseline to week 24 between dapagliflozin 10 mg versus placebo.
Measured: Baseline to Week 24
Adjusted Mean Change in Seated Systolic Blood Pressure (SBP) at Week 8 (LOCF) in Participants With Baseline SBP>=130 mmHg
To compare the mean change in seated systolic blood pressure (SBP) in participants with baseline seated SBP ≥130 mmHg achieved with dapagliflozin versus placebo from baseline to week 8.
Measured: Baseline to Week 8

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

Mar 2010Dec 2012

First posted6 Jan 2010 (estimated)
Study startMar 2010
Primary completionMay 2011
Study completionDec 2012

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (1)Papers the sponsor has linked to this study.
Other trials for Type 2 Diabetes MellitusStudies of the same condition, open and under way.
More trials run by AstraZenecaThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind
Who is masked: Participant, Care provider, Investigator, Outcomes assessor
Enrolment: 964 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT01042977
Sponsor's protocol ID: D1690C00019
Status last verified: Dec 2013
First submitted: 5 Jan 2010
Last updated: 17 Feb 2014
Results posted: Yes, on ClinicalTrials.gov

Publications

Natale P, Tunnicliffe DJ, Toyama T, Palmer SC, Saglimbene VM, Ruospo M, Gargano L, Stallone G, Gesualdo L, Strippoli GF. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2024 May 21;5(5):CD015588. doi: 10.1002/14651858.CD015588.pub2.
PubMed 38770818

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)

All Type 2 Diabetes Mellitus trials

Study at a glance

From the registry record, last updated by the sponsor on 17 Feb 2014. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A 24-week, Multicentre, Randomised, Double-blind,Age-stratified, Placebo Controlled Phase III Study With an 80-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin 10 mg Once Daily in Patients With T2DM and Cardiovascular Disease, Who Exhibit Inadequate Glycaemic Control on Usual Care
ClinicalTrials.gov ID: NCT01042977
Acronym / sponsor ID: D1690C00019
Conditions: Type 2 Diabetes Mellitus, Cardiovascular Disease, Inadequate Glycaemic Control
Keywords: dapagliflozin, diabetes, cardiovascular disease
Phase: Phase 3
Study type: Interventional
Recruitment status: Completed
Enrolment: 964 participants (actual)
Lead sponsor: AstraZenecaIndustry (pharma, biotech, devices)
Collaborators: Bristol-Myers Squibb
Study start: Mar 2010
Primary completion: May 2011 (actual)
Study completion: Dec 2012 (actual)
First posted: 6 Jan 2010 (estimated)
Results: Posted 23 Aug 2013

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind (participant, care provider, investigator, outcomes assessor)
Number of arms: 2

Arm	Type	Receives
1	Experimental	Drug: Dapagliflozindapagliflozin 10 mg tablet
2	Placebo comparator	Drug: Placebomatching placebo tablet

Who may qualify

Ages: 45 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (3 listed)

Type 2 diabetes mellitus.
Cardiovascular disease
Uninterrupted anti-diabetic treatment for at least 8 weeks before enrolment

Key exclusion criteria (3 listed)

Patients with type 1 diabetes or diabetes insipidus
Patients with 3 or more oral anti-hyperglycaemic drugs with or without insulin and/or poorly controlled diabetes
Any clinically significant illness, which would compromise the patient's safety and their participation in the study

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Dapagliflozin10 mg tablet, oral, once daily, 24- week treatment and 80-week extension period	Drug	1
Placebomatching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period	Drug	2

Primary outcome

Adjusted Mean Change in HbA1c Levels
Time frame: Baseline to Week 24
To compare the glycemic efficacy of dapagliflozin 10 mg versus placebo when added to usual care in type 2 diabetes patients with cardiovascular disease, measured as the mean change in HbA1c from baseline to week 24.
Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit
Time frame: Baseline to Week 24
To compare the clinical benefit of dapagliflozin 10 mg versus placebo when added to usual care in type 2 diabetes patients with cardiovascular disease at week 24, measured as the proportion of responders for a 3-item endpoint of clinical benefit, defined as an absolute drop of 0.5% or more from baseline HbA1c, and a relative drop of 3% or more from baseline for total body weight, and an absolute drop of 3 mmHg or more from baseline in seated systolic blood pressure.

5 secondary outcomes

Adjusted Mean Percent Change in Body Weight
Time frame: Baseline to Week 24
Proportion of Participants With a Reduction From Baseline of 5% or More in Body Weight in Participants With Baseline BMI ≥27 kg/m²
Time frame: Baseline to Week 24
Adjusted Mean Change in Systolic Blood Pressure at Week 8 (LOCF)
Time frame: Baseline to Week 8
Adjusted Mean Change in Seated Systolic Blood Pressure at Week 24 (LOCF)
Time frame: Baseline to Week 24
Adjusted Mean Change in Seated Systolic Blood Pressure (SBP) at Week 8 (LOCF) in Participants With Baseline SBP>=130 mmHg
Time frame: Baseline to Week 8

Results and safety

Results posted to the registry on 23 Aug 2013, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Dapagliflozin	482	441
Placebo	483	428

Primary outcome: Adjusted Mean Change in HbA1c Levels

Time frame: Baseline to Week 24. Least squares mean (95% Confidence Interval). Unit: Percent

Measure	Dapagliflozin n = 474	Placebo n = 471
Value	-0.33 (0.0434)	0.07 (-0.02 to 0.15)

Dapagliflozin vs Placebo: Mean Difference (Final Values): -0.40 (95% CI -0.50 to -0.30), p <0.0001, ANCOVA

Population analysed: Full Analysis Set, participants with non-missing baseline and Week 24 (LOCF) values

Primary outcome: Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit

Time frame: Baseline to Week 24. Number (95% Confidence Interval). Unit: Percentage of participants

Measure	Dapagliflozin n = 468	Placebo n = 469
Value	10.0 (0.7)	1.9 (7.3)

Dapagliflozin vs Placebo: Risk Difference (RD): 7.0 (95% CI 4.3 to 9.8), p <0.0001, Cochran-Mantel-Haenszel

Population analysed: Full Analysis Set, subjects with non-missing baseline and Week 24 (LOCF) values

5 secondary outcomes are reported in the full results.

Adverse events

Time frame: Non-serious / serious adverse events on or after the first day and on or prior to the last day of the 24-week double-blind treatment plus 4/30 days or up to follow-up visit if earlier, or up to and including the start date of extension period if earlier.. Other adverse events reported at 5% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Dapagliflozin	41 of 482 (8.5%)	147 of 482 (30.5%)	Not reported
Placebo	46 of 483 (9.5%)	134 of 483 (27.7%)	Not reported

Limitations and caveats (from the sponsor): For participants who did not complete 8 and/or 24 weeks, respectively, LOCF was used. For HbA1c: excluding data after glycemic rescue, Weight: including data after rescue, SBP: excluding data after anti-hypertensive rescue.

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 17 Feb 2014.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Derived from this study: PubMed 38770818Natale P, Tunnicliffe DJ, Toyama T, Palmer SC, Saglimbene VM, Ruospo M, Gargano L, Stallone G, Gesualdo L, Strippoli GF. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2024 May 21;5(5):CD015588. doi: 10.1002/14651858.CD015588.pub2.

Related trials for Type 2 Diabetes Mellitus

Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Dr. Lawrence A Leiter, MD principal investigator

Division of Endocrinology & Metabolism, St Michael's Hospital

135 sites in 10 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Dapagliflozin in people with Type 2 Diabetes Mellitus and Cardiovascular Disease, run by AstraZeneca at 135 sites in 10 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Feb 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 135 sites in United States, Poland, Australia, Canada, Hungary and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 23 Aug 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Adjusted Mean Change in HbA1c Levels (time frame: Baseline to Week 24). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01042977, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2014.